JTE-907

JTE-907 is a cannabinoid 2 (CB2) receptor inverse agonist. It is selective for CB2 over CB1 receptors (Kis = 35.9 and 2,370 nM, respectively, for the human receptors). JTE-907 increases forskolin-induced cAMP production in CHO cells expressing human or mouse CB2 receptors in a concentration-dependent manner. It promotes the differentiation of isolated mouse splenic CD4+ T cells into regulatory T cells (Tregs) when used at a concentration of 100 nM and decreases disease severity in a mouse model of inflammatory bowel disease (IBD) induced by dinitrobenzene sulfonic acid (DNBS). JTE-907 (1 and 10 mg/kg) inhibits spontaneous scratching in a mouse model of chronic dermatitis, as well as reduces carrageenan-induced paw edema in mice (ED50 = 0.05 mg/kg). Bilateral injection of JTE-907 (25 pmol/animal) into the anterior bed nucleus of the stria terminalis decreases the percentage of time spent in the open arms of the elevated plus maze in mice, indicating anxiety-like behavior.Formal Name: N-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide. CAS Number: 282089-49-0. Molecular Formula: C24H26N2O6. Formula Weight: 438.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 16.6 mg/ml, DMF:PBS (pH 7.2) (1:2): 0.2 mg/ml, DMSO: 0.16 mg/ml, Methanol: 1 mg/ml. lambdamax: 222, 264, 331 nm. SMILES: O=C1NC2=C(OCCCCC)C(OC)=CC=C2C=C1C(NCC3=CC=C(OCO4)C4=C3)=O. InChi Code: InChI=1S/C24H26N2O6/c1-3-4-5-10-30-22-19(29-2)9-7-16-12-17(24(28)26-21(16)22)23(27)25-13-15-6-8-18-20(11-15)32-14-31-18/h6-9,11-12H,3-5,10,13-14H2,1-2H3,(H,25,27)(H,26,28). InChi Key: GRAJFFFXJYFVOC-UHFFFAOYSA-N.